About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Stereotaxis (STXS) announced initial clinical results for its MAGiC catheter, marking the first peer-reviewed evidence of its safety and efficacy in treating cardiac arrhythmias [1][4] - The MAGiC catheter is the first robotic, fully integrated radiofrequency ablation catheter designed for use with Stereotaxis' Robotic Magnetic Navigation system, demonstrating consistent navigation accuracy and a strong safety profile [2][4] Company Performance - Following the announcement, STXS shares remained flat, with a year-to-date decline of 3.5%, compared to the industry's 7.4% decline and the S&P 500's gain of 6.3% [3] - The company currently has a market capitalization of $189.2 million [6] Clinical Study Results - The MAGiC catheter study involved 67 patients, showing an acute efficacy rate of 94% and a low procedure-related adverse event rate of 1.5% [7][8] - The study reported no adverse events linked to catheter malfunction, with an average procedure time of 83 minutes [8] Technological Advancements - The MAGiC catheter demonstrated improved stability, steady tip temperatures during ablation, and low irrigation rates, enhancing safety and efficiency in robotic ablation procedures [9] - These advancements are expected to boost physician confidence and accelerate the adoption of Stereotaxis' robotic system [4] Industry Outlook - The global market for robotic catheterization systems is projected to grow from $54.4 million in 2025 to $190.2 million by 2035, driven by the demand for minimally invasive procedures [10][11]

这与 Brainlab 一贯的经营风格一致。作为一家深耕全球高端医疗器械市场的企业，Brainlab 多年来始终保持稳健的现金流。公司特别强调， 即便取消 IPO， Brainlab 的资金实力仍足以支持未来的有机增长，无需急于依赖外部融资。 招商通知： 第三届全球手术机器人大会 2025年7月，德国医疗科技领军企业 博医来Brainlab 宣布 推迟其原定在法兰克福证券交易所的首次公开募股（IPO）计划。 虽然此次 IPO 已获得市场超额认 购，反响颇为积极，但 Brainlab 管理层在审慎考量后，仍决定按下"暂停键"。 这家在神经外科手术导航领域拥有全球60%市场份额、被誉为"手术导航金标准"的创新型企业，在行业动荡与地缘政治风险的背景下，展现出对技术主导型企 业未来发展节奏的深刻把握。 # 超额认 购背后，却选择 谨 慎 根据 Brainlab 此前提交的招股文件，公司原计划发行 200 万股新股，并转让最多 320 万股现有股份，拟募集约 4.16 亿欧元（折合人民币超 30 亿元），定价区 间为每股 80-100 欧元。按最高发行价计算，Brainlab 的估值可达 17 亿欧元（约合人民币 14 ...

Core Viewpoint - Garmin is expected to report strong earnings growth and revenue increase in its upcoming earnings disclosure, indicating positive business trends Group 1: Stock Performance - Garmin closed at $208.36, reflecting a +1.56% change from the previous day, outperforming the S&P 500's gain of 0.52% [1] - Over the past month, Garmin's shares gained 1.14%, underperforming the Computer and Technology sector's 9.55% gain and the S&P 500's 5.95% gain [1] Group 2: Earnings and Revenue Estimates - Garmin is projected to report earnings of $1.95 per share, representing a year-over-year growth of 23.42%, with revenue expected to be $1.73 billion, a 15.01% increase compared to the previous year [2] - For the entire year, the Zacks Consensus Estimates forecast earnings of $7.99 per share and revenue of $6.83 billion, indicating changes of +8.12% and +8.48% respectively compared to the previous year [3] Group 3: Analyst Estimates and Rankings - Recent adjustments to analyst estimates for Garmin reflect short-term business trends, with positive revisions indicating analyst optimism about profitability [3] - Garmin currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having moved 2.16% higher over the past month [5] Group 4: Valuation Metrics - Garmin's Forward P/E ratio is 25.67, which is a premium compared to the industry average Forward P/E of 19.04 [6] - The company has a PEG ratio of 2.3, compared to the Electronics - Miscellaneous Products industry's average PEG ratio of 1.74 [7] Group 5: Industry Context - The Electronics - Miscellaneous Products industry, part of the Computer and Technology sector, has a Zacks Industry Rank of 149, placing it in the bottom 40% of all industries [8]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - Stocks are rated based on value, growth, and momentum characteristics, with scores ranging from A to F, where A indicates the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive stocks based on valuation ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Score assesses stocks based on projected and historical earnings, sales, and cash flow, targeting growth investors [4] Momentum Score - The Momentum Score helps investors capitalize on price trends and earnings outlook changes, focusing on short-term price movements [5] VGM Score - The VGM Score combines the three Style Scores to provide a comprehensive rating, highlighting stocks with strong value, growth, and momentum characteristics [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] - To maximize returns, investors should consider stocks with a Zacks Rank of 1 or 2 alongside Style Scores of A or B [9] Stock Highlight: Garmin (GRMN) - Garmin, based in Olathe, Kansas, is rated 3 (Hold) on the Zacks Rank and has a VGM Score of A, indicating potential for momentum investors [11] - Recent upward revisions in earnings estimates for fiscal 2025 have increased the Zacks Consensus Estimate by $0.08 to $7.99 per share, with an average earnings surprise of 17.7% [12]

SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted US Patent No. 12,311,127 titled "Radial and Trans-endocardial Delivery Catheter". US Patent No. 12,311,127 describes the Company's minimally invasive interventional catheter systems to deliver biologic therapies to target sites in the heart. T ...

June 24, 2025 • San Diego, CA Disclaimer and Statement Regarding Use of Non-GAAP Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may relate to, but are not limited to, expectations of future operating results or financial performance, customer expansion opportunities, market size and growth opportunities, industry developments and trends, the calculation of ...

机器之心报道 机器之心编辑部 刚刚，在美国田纳西州纳什维尔举办的 CVPR 2025 公布了最佳论文等奖项。 今年共有 14 篇论文入围最佳论文评选，最终 5 篇论文摘得奖项 ，包括 1 篇最佳论文 、 4 篇最佳论文荣誉提名 。此外，大会还颁发了 1 篇最佳学生论文 、 1 篇最 佳学生论文荣誉提名 。 根据会方统计，今年大会共收到 4 万多名作者提交的 13008 份论文。相比去年（11532），今年的投稿数量增长了 13%，最终有 2872 篇论文被接收，整体接收率 约为 22.1%。在接收论文中，Oral 的数量是 96（3.3%），Highlights 的数量是 387（13.7%）。 计算机视觉技术的火热给大会审稿带来了空前的压力。本届投稿作者数量、论文评审者和领域主席（AC）数量均创下新高。 今年前来现场参会的学者也超过 9000 人，他们来自 70 余个国家和地区。 CVPR 官方公布了各个细分领域的论文接收情况，如下图所示。可以看到，图像与视频生成领域今年度的论文接收数量最多，而接收率最高的领域则是基于多视角 和传感器的 3D 以及基于单图像的 3D。 此次，最佳论文奖委员会成员中有 AI ...

Core Insights - The article emphasizes the importance of utilizing Zacks Premium for investors to enhance their stock market strategies and confidence in investing [1][2] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks with the highest potential to outperform the market within a 30-day timeframe, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [4] - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow [5] - The Momentum Score capitalizes on price trends and earnings outlook changes, using metrics like one-week price change and monthly earnings estimate changes [6] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [7] Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors, highlighting the need for Style Scores to aid in stock selection [10] Stock Example: Garmin (GRMN) - Garmin, Ltd. is identified as a stock to watch, currently rated 3 (Hold) with a VGM Score of B, and a Momentum Style Score of A, having increased by 5.2% in the past four weeks [12] - Analysts have revised Garmin's earnings estimate upward for fiscal 2025, with the Zacks Consensus Estimate rising by $0.08 to $7.94 per share, and an average earnings surprise of 17.7% [13]

Zimmer Biomet (ZBH) FY Conference June 09, 2025 09:20 AM ET Speaker0 Okay. Good morning, everyone. We'll go ahead and get started here. Very pleased to welcome Ivan Tornos, Chairman and CEO of Zimmer Biomet and Sukhi Upade, Executive Vice President and CFO. As with all of these sessions, if you have a question, feel free to raise your hand. I certainly have have plenty to keep us to keep us going here, but obviously, we wanna keep this as interactive as possible. So why don't we start with with a topic that ...